Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic cyst antibiotic penetration study
NL-OMON46163Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2019
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ciprofloxacin, trimethoprim + sulfamethoxazole, doxycycline and piperacillin + tazobactam in hepatic cyst and Polycystic liver disease (PLD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Hepatic cyst penetration of antibiotics. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
ciprofloxacintrimethoprim + sulfamethoxazoledoxycyclinepiperacillin + tazobactam
03
Conditions
hepatic cystPolycystic liver disease (PLD)
Beyond the preview
Go deeper on NL-OMON46163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46163.